Hengan Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Hengan International Group Co ( (HK:1044) ) is now available.
Hengan International Group Company Limited has scheduled a board meeting for 17 March 2026 to review and approve the audited final results for the financial year ended 31 December 2025. The board will also consider the declaration and payment of a final dividend, a decision that could signal management’s confidence in the group’s financial performance and capital-return policy, with implications for shareholder income and market perception.
The announcement, dated 2 March 2026, confirms that both executive and independent non-executive directors will participate in the meeting, underscoring corporate governance oversight in the approval of results and dividend deliberations. Investors and other stakeholders are likely to watch the outcome closely, as the final results and any proposed dividend will provide an updated view on profitability, cash flow strength, and the company’s stance on balancing growth investment with shareholder returns.
The most recent analyst rating on (HK:1044) stock is a Hold with a HK$24.60 price target. To see the full list of analyst forecasts on Hengan International Group Co stock, see the HK:1044 Stock Forecast page.
More about Hengan International Group Co
Hengan International Group Company Limited is a Hong Kong-listed company incorporated in the Cayman Islands and traded under stock code 1044. The group operates through a board of executive and independent non-executive directors and is engaged in consumer-related manufacturing and distribution, with a focus on the Chinese and broader Asian markets.
YTD Price Performance: 4.59%
Average Trading Volume: 2,720,736
Technical Sentiment Signal: Hold
Current Market Cap: HK$33.87B
For a thorough assessment of 1044 stock, go to TipRanks’ Stock Analysis page.
